Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort

ObjectivesImmunotherapy plus chemotherapy has recently been applied in the neoadjuvant treatment for locally advanced gastric cancer (LAGC), while its superiority over neoadjuvant chemotherapy (NACT) alone remains to be explored. This study explored the safety and efficacy of NACT plus tislelizumab...

Full description

Bibliographic Details
Main Authors: Qi Jiang, Weizhen Liu, Xiangyu Zeng, Chenggang Zhang, Yuqiang Du, Liwu Zeng, Yuping Yin, Jun Fan, Ming Yang, Kaixiong Tao, Peng Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
neoadjuvant chemotherapy
gastric cancer
tislelizumab
gastrectomy
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1122121/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1122121/full

Similar Items